瑞巴派特对门脉高压性胃病的临床疗效观察

The clinical therapeutic effect of Rebamipide on portal hypertensive gastropathy

目的评价瑞巴派特对门脉高压性胃病的临床疗效及安全性。方法将患者随机分为正常对照组、正常干预组、空白对照组及试验组各15例,其中正常干预组及试验组给予口服瑞巴派特治疗4周。观察治疗前后临床症状积分和内镜表现的变化。结果治疗前试验组与空白对照组的症状积分无显著性差异,而药物治疗4周后试验组患者剑突下疼痛、上腹不适、烧心等症状明显缓解,与治疗前相比,差异有显著性(P<0.01),腹胀虽有缓解,但不如前者明显(P>0.05);而空白对照组则症状无缓解;试验组的总有效率为85.7%。治疗前试验组有胃窦和/或胃体水肿糜烂,甚至呈mosaic样改变,治疗后这些表现明显改善。结论瑞巴派特能改善门脉高压性胃病患者的临床症状及胃黏膜病变。

Objective To evaluate the clinical therapeutic effect and security of Rebamipide on portal hypertensive gastropathy. Methods Thirty healthy subjects and thirty patients were involved in this study. The former were randomized into either normal control group or normal intervention group, the latter into either blank control group or trial group. There were 15 subjects in every group. Normal intervention group and trial group were treated with Rebamipide for 4 weeks. Endoscopy was performed. The change of clinical symptom scores and endoscopic appearance at baseline and again after the treatment were observed. Results At baseline, there was no significant difference of symptom scores between trial group and blank control group. However, after the treatment in trial group, complaints such as abdominal pain under the xiphoid process, upper abdominal discomfort and heartburn were obviously alleviated（ P 〈 0.01 ）. Although flatulence was somewhat catabatic, it＇s not distinct（ P 〉 0.05）. Symptoms in blank control group were not alleviated. The total efficacy rates of trial group was 85.7%. At baseline, there were edema and erosion, even mosaic-like appearance in the antrum and/or corpus, which were significantly ameliorated. Conclusion Rebamipide can ameliorate the clinical symptoms and pathological changes of gastric mucosa in portal hypertensive gastropathy.